肿块型肝内胆管癌影像:从检出到个体化治疗
本文围绕欧洲最常见的肝内胆管癌表型肿块型肝内胆管癌(MF-iCCA),综述影像在检出、鉴别、分期、可切除性评估及疗效评价中的作用。CT与MRI是诊断基础,MRI结合DWI和肝胆期序列对肝内分期和肿瘤勾画更敏感,CEUS用于鉴别诊断,18F-FDG-PET在淋巴结分期中具有增量价值。个体化治疗时代,功能性疗效标准日益重要,熟悉治疗后影像表现可避免将治疗反应误判为进展。
要点
- MRI结合DWI和肝胆期序列对肝内分期和肿瘤勾画敏感性更高,报告时应充分评价。
- 可切除性评估需重点关注血管受累、未来残肝体积和转移播散。
- 解读治疗后影像须熟悉预期表现,避免将治疗相关改变误判为疾病进展。
核心结论
- 影像贯穿MF-iCCA从检出、鉴别、分期、疗效评估到个体化治疗选择的全过程。
研究设计与样本
- 叙述性综述,概述MF-iCCA的影像特征、分期与可切除性评估、个体化治疗选择及治疗后影像表现。
关键影像表现/征象
- MRI增强扫描结合DWI和肝胆期序列可提高肝内分期和肿瘤勾画敏感性。
- CT提供优越的空间分辨率,用于血管评估。
- CEUS可作为鉴别诊断的有用补充工具。
诊断标准与关键数值
- 仅20%–30%的MF-iCCA患者适合根治性切除。
- 可切除性评估需评价血管受累、未来残肝体积和转移播散。
- 个体化治疗时代,需要超越RECIST 1.1的功能性疗效评价标准。
- 18F-FDG-PET在淋巴结分期中具有增量作用。
临床应用与阅片要点
- 阅片时对血管受累情况需细致评价,CT在血管评估上优于MRI。
- 肝内分期和肿瘤范围勾画应优先参考MRI的DWI和肝胆期序列。
- 随访中识别正常治疗后改变与真实进展需结合功能性疗效标准。
- 术前评估应记录未来残肝体积,尤其在考虑扩大切除时。
局限性
- 原文为叙述性综述,未提供系统检索策略或纳入文献的定量分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Mass-forming intrahepatic cholangiocarcinoma (MF-iCCA) represents the most frequent phenotype of intrahepatic CCA in Europe, yet its insidious clinical onset and tendency toward late presentation translate into a poor prognosis, with only 20-30% of patients eligible for curative resection. In this context, imaging plays a pivotal role, spanning from initial lesion detection and characterization to staging, treatment selection, and response assessment. Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) constitute the backbone of diagnostic workup, with complementary strengths: CT offers superior spatial resolution for vascular assessment, while MRI, enhanced by diffusion-weighted imaging (DWI) and hepato-biliary phase sequences, provides higher sensitivity for intrahepatic staging and tumor delineation. Contrast-enhanced ultrasound (CEUS) serves as a valuable adjunct for differential diagnosis. Accurate resectability assessment requires careful evaluation of vascular involvement, future liver remnant (FLR) volume, and metastatic spread, with 18 F-FDG-PET playing an incremental role in nodal staging. In the era of personalized therapy, including chemo-immunotherapy, targeted agents, and locoregional treatments, functional response criteria beyond RECIST 1.1 are increasingly essential. A thorough knowledge of expected post-treatment imaging appearances is critical to avoid misclassification of treatment effects as disease progression. This narrative review aims to provide a comprehensive, imaging-focused overview of MF-iCCA, covering its radiological features and differential diagnosis, the role of imaging in staging and resectability assessment, imaging-based criteria guiding personalized treatment selection, and expected post-treatment imaging findings.
引用
- Maino, Franco, Vizzuso, et al. Imaging of mass-forming intrahepatic cholangiocarcinoma: from detection to personalized treatments. Abdom Radiol (NY). 2026. PMID: 42820954. doi:10.1007/s00261-026-05773-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。